Canadian Cancer Trials Group Bulletins

Trial Management Group

Trial Closures

CM.1 -- A Phase IIB Study of Molecular Responses to Imatinib at Standard or Increased Doses or Dasatinib (BMS 354825) (NSC-732517) for Previously Untreated Patients with Chronic Myelogenous Leukemia (CML) in Chronic Phase -- was closed 28 February 2009 after achieving its accrual goal.

LY.13 -- A Multi-Centre Phase II Trial Investigating the Efficacy and Tolerability of Bortezomib Added to Cyclophosphamide, Vincristine, Prednisone and Rituximab (BCVP-R) for Patients with Advanced Stage Follicular Non-Hodgkin's Lymphoma Requiring Systemic First-Line Treatment -- was closed 6 March 2009 after achieving its accrual goal.